Search for: "PFIZER V APOTEX"
Results 41 - 60
of 211
Sorted by Relevance
|
Sort by Date
18 Jun 2007, 8:19 pm
"KSR and Pfizer v. [read post]
1 Jun 2007, 9:05 am
The application (Pfizer v. [read post]
22 Mar 2007, 1:18 pm
Pfizer, Inc. v. [read post]
24 Mar 2016, 4:00 am
The Federal Court recently held, in Apotex Inc. v. [read post]
25 Oct 2013, 6:02 am
While evidence of unexpected resultscan be used to rebut a primafacie case of obviousness,Pfizer, Inc. v. [read post]
3 Mar 2008, 9:27 pm
Pfizer, Inc. v. [read post]
30 Apr 2007, 9:07 am
Mylan Labs. et al. v. [read post]
16 Sep 2007, 5:50 pm
The Federal Circuit reissued its July 11 opinion in Daiichi Sankyo v. [read post]
2 Apr 2007, 9:52 pm
Mutual Zantac Syrup: Apotex v. [read post]
6 May 2007, 9:06 pm
Apotex Norvasc: Pfizer v. [read post]
2 Apr 2008, 5:55 am
Apotex,432 F. [read post]
2 Jul 2007, 2:51 pm
Apotex Lipitor: Pfizer v. [read post]
25 Jan 2007, 7:16 pm
Andrx Detrol: Pfizer v. [read post]
18 Nov 2016, 12:44 am
John Collins, Sumer Dayal and Natalie ShoolmanClayton Utz by John Collins, Natalie Shoolman & Sumer Dayal On 21 October 2016, the Federal Court of Australia handed down its judgment in the case of Apotex Pty Ltd v Warner-Lambert Company LLC (No 2) [2016] FCA 1238 (FCA Judgment). [read post]
29 Jan 2014, 9:12 pm
Apotex, Inc., 480 F.3d 1348, 1372 (Fed. [read post]
6 Aug 2007, 8:38 pm
Ranbaxy Cases removed Zithromax: Pfizer v. [read post]
27 Apr 2011, 4:55 am
Highlights this week included: Pfizer starts R&D in China after IPR in China challenges (IP Dragon) Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored. [read post]
10 Feb 2014, 2:01 am
Perhaps the most important exclusion from patentability, discussed further below, is India’s Section 3(d).The authors cited Pfizer v. [read post]
16 Sep 2013, 4:00 am
Regarding obviousness, the FCA disagreed with the trial judge’s approach to framing the Apotex v. [read post]
20 Mar 2014, 4:15 am
At the time of the IPR filings Apotex was involved in litigation while Ranbaxy was not although the patents had been asserted against others, see IPRs 2013-00012 (Apotex v Alcon), 00015 (Apotex v Alcon), and 00024 (Ranbaxy v Vertex). [read post]
